sibly acting via an increase in somatostatin release, is able to inhibit GH release in response to direct pituitary Background. Several alterations in growth hormone (GH ) secretion have been reported in patients with stimulation with GHRH. chronic renal insufficiency. However, cholinergic Key words: chronic renal failure; growth hormone; modulation of somatotopic cell function has not been growth hormone-releasing hormone; peritoneal diafully clarified in uraemic patients. To gain further lysis; pirenzepine insight into the disrupted mechanism of GH regulation in chronic renal failure, we investigated whether the blockade of cholinergic muscarinic receptor with pirenzepine could modify the response of GH to its physio-Introduction logical releasing hormone.
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Methods. Eight uraemic male patients on peritoneal
Several derangements in growth hormone (GH ) secredialysis and six normal controls were studied. All tion have been described in patients with chronic renal subjects underwent two endocrine tests in random failure. Baseline GH levels have been found to be order. In one of them placebo was administered 60 min increased [1] [2] [3] , and exaggerated responses to several before the injection of GH-releasing hormone (GHRH, pharmacological stimuli such -dopa [2,3] or arginine 100 mg, i.v. in bolus at 0 min). In another the muscar- [4] have been reported. Insulin- [5] and tolbutamideinic blocking agent pirenzepine, 100 mg p.o., was
[3] induced hypoglycaemia fails to adequately release administered at that time. Blood samples for GH were GH in uraemic patients. Paradoxical responses of GH collected at −60, 0, 15, 30, 45, 60 and 90 min.
after administration of thyrotropin-releasing hormone Results. Baseline plasma GH concentrations were sim- [3, 6 ] or glucose [1, 3] are also frequently observed in ilar in patients and controls. GH responses to GHRH patients with renal insufficiency. In haemodialysis were characterized by great interindividual variability patients, GH responses to direct pituitary stimulation in uraemic patients with regard to the amount and the with GH-releasing hormone (GHRH ) have been found time to maximal peak. In the placebo plus GHRH to be exaggerated both in children [7] and adults [8, 9] , test, the maximum GH concentrations in patients although some investigators have found normal (14.0±3.2 mg/l ) were similar to those reached by conresponses [10, 11] . Derangements in GH and its major trols (18.0±3.1 mg/l ), although GH secretion was mediator, insulin-like growth factor type I (IGF-I ), more sustained in patients. The area under the secretappear related to several alterations that accompany ory curve (AUC ) of GH secretion in patients was also uraemia, such as growth retardation and the failure to similar to that found in controls (14.4±2.9 vs obtain an optimal final adult height in children, and 15.4±3.3 mg/h/l ). When subjects were given pirenzepdecreased anabolism, malnutrition and metabolic ine before GHRH injection an abolishment of GHRHabnormalities, mainly carbohydrate intolerance, in induced GH release was observed in all controls and adult patients [1, 3, 5, 7] . in all but one of the uraemic patients. The AUC of Over the last two decades it has become evident that GH secretion was, therefore, significantly reduced both hypothalamic cholinergic neurotransmission plays a in uraemic patients (4.1±2.0 mg/h/l, P<0.05) and in major role in the regulation of GH secretion [12] . control subjects (2.0±0.3 mg/h/l, P<0.05).
Cholinergic agents and cholinergic tonus enhancement Conclusion. These results suggest that GH secretion in by cholinesterase inhibitors, such as pyridostigmine, uraemic patients is modulated, at least in part, by a enhance GH secretion in normal subjects [13] [14] [15] [16] [17] . cholinergic mechanism. The muscarinic blockade, posPyridostigmine is able to reduce the release of somatostatin from the hypothalamus [18] [19] [20] , increasing basal Correspondence and offprint requests to: Juan J. Díez, M.D., Travesía GH release and potentiating GHRH-induced GH Muscarinic blockade in uraemia 1705 random order on different days with an interval of at least endogenous cholinergic pathways causes a striking 3 days, and 8-9 h after the last dialysate exchange in PD reduction in basal and stimulated GH release patients. In all blood samples plasma GH concentrations [13, 15, [23] [24] [25] [26] [27] [28] . Atropine [29] and pirenzepine [23, 25] , were assessed. Blood haemoglobin concentration and haembut not nicotine [29] , block GH secretion, thus sug-atocrit values and serum concentrations of urea, creatinine, gesting the involvement of a muscarinic receptor. calcium, phosphorus, total proteins, albumin, cholesterol, Cholinergic modulation is an aspect of GH secretion triglycerides, IGF-I, free thyroxine, thyrotropin and prolactin that remains to be clarified in patients with renal were also determined at time 0 in one of the experiments. insufficiency. To date it is not known whether an impairment of cholinergic neurotransmission might be Blood analysis and hormone assay implicated in the derangements in GH secretion found in uraemic patients. Therefore, the present study was Blood samples were centrifuged immediately and the plasma performed with the aim of investigating the effects of stored at −20°C until assayed. Blood haemoglobin concenmuscarinic blockade with pirenzepine on GH release tration and haematocrit values were measured in a Coulter after GHRH stimulation in patients with chronic renal counter, and the serum chemistry determinations were made insufficiency undergoing peritoneal dialysis (PD).
using an automated multichannel analyser. Human plasma GH concentrations were determined by using an automated immunoenzymatic assay (AIA 1200, Tosoh Corporation,
Subjects and methods
Tokyo, Japan). Maximal intra-assay and interassay coefficients of variation of GH assay were 5.4 and 3.3%, respectively. The sensitivity of the GH assay was 0.1 mg/l. IGF-I Patients concentrations were determined using commercially available radioimmunoassay kits (Nichols Institute, San Juan Eight male patients with chronic renal insufficiency were Capistrano, CA, USA) after extraction by acid-ethanol prestudied. The control group consisted on six healthy volunteers cipitation. Maximal intra-and interassay coefficients of variwith normal renal function. There were no significant differation were 3.0 and 8.4%, respectively, and the sensitivity of ences between patients and controls with regard to age, the assay was 13.5 mg/l. Plasma thyrotropin and prolactin weight, and body mass index. The study was approved by concentration were also determined by using the Tosoh the local ethical committee, and informed consent was immunoenzymatic assay. For thyrotropin assay, the sensitivobtained from all study participants before testing. Four ity was 0.06 mU/ml, and maximal intra-assay and interassay patients had end-stage renal disease due to chronic glomcoefficients of variation were 3.3 and 3.4%, respectively. For erulonephritis, three had interstitial nephropathy and one prolactin assay the sensitivity and maximal intra-assay and had polycystic kidney disease. The main clinical and analytinterassay coefficients of variation were, respectively, 1 mg/l, ical data of studied patients and controls are shown in Table  and 6 and 4.5%. A heterogeneous competitive immunoassay 1. All patients were on PD for at least 6 months (range 6-34 (Immuno 1 System; Miles, Tarrytown, NY, USA) was used months). There were seven patients on continuous ambulatto quantify free thyroxine concentrations. ory PD and one patient on continuous cycling PD. Patients on continuous ambulatory PD performed three or four 2-l bag exchanges per day. Dialysis solutions with 1.5-4.25% Statistical methods dextrose were used. The weekly glucose load ranged from 780 to 1475 g with a mean of 1180 g. All patients were on a Results are expressed as mean±SEM throughout. The GH stable diet containing~30-35 kcal/kg/day and~1 g/kg secretory responses are expressed either as absolute values protein per day. They were found to be stable clinically, and (mg/l ) or areas under the curve (AUC, mg/h/l ) calculated by none received erythropoietin therapy. All patients were trapezoidal integration between 0 and 90 min. Peak GH was treated with aluminium hydroxide and water-soluble vit-considered in each test as the maximum level reached by GH amins. None of them had diabetes mellitus, severe secondary concentrations regardless of the time taken to do so. The hyperparathyroidism or other endocrine disorder. Five changes in peak and AUC induced by pirenzepine plus patients were hypertensive. Four of them were treated with GHRH in relation to placebo plus GHRH stimulation were calcium-channel blockers or angiotensin-converting enzyme considered in absolute values and in per cent values. For inhibitors with adequate control of blood pressure. A further each patient and control subject the following parameters patient was controlled by a beta-adrenergic blocker agent.
were calculated: DPeak GH after pirenzepine plus GHRH (mg/l )=peak GH after pirenzepine plus GHRH (mg/l )-peak GH after placebo
Study design
plus GHRH (mg/l ), %DPeak GH after pirenzepine plus GHRH=DPeak GH Endocrine tests started at 09:00, after an overnight fast with the subjects in the recumbent position. An indwelling catheter after pirenzepine plus GHRH (mg/l )/peak GH after placebo plus GHRH (mg/l )×100, was placed in an antecubital vein and kept patent by slow infusion of saline. Thirty minutes later, the first blood sample DAUC GH after pirenzepine plus GHRH (mg/h/l )=AUC GH after pirenzepine plus GHRH (mg/h/l )-AUC GH after was collected. Each subject received GHRH (GHRH-1-29, Geref; Serono, Spain), 100 mg, i.v. in bolus at 0 min. Blood placebo plus GHRH (mg/h/l ), and %DAUC GH after pirenzepine plus GHRH=DAUC GH samples were collected 60 min and immediately before the injection of GHRH and then 15, 30, 45, 60 and 90 min after after pirenzepine plus GHRH (mg/h/l )/AUC after placebo plus GHRH (mg/h/l )×100. the stimulus. All subjects underwent two endocrine tests. In one experiment placebo was administered p.o. 60 min before For statistical evaluation of the GH responses after placebo plus GHRH and after pirenzepine plus GHRH administrathe GHRH injection. In another one, pirenzepine (Gastrozepin; Boehringer Ingelheim, Germany), 100 mg, was tion, the obtained values were analysed using the Wilcoxon signed-rank test. For comparisons between patients and administered orally at that time. Tests were performed in control subjects, the Mann-Whitney U-test was employed. patients regarding the amount and the time to maximal The differences were considered to be significant if the P-peak. In uraemic patients, GHRH injection 60 min value was <0.05. after oral placebo administration was followed by an increment in GH concentration that reached a maximum of 14.0±3.2 mg/l at 30-90 min, due to the great
Results
interindividual variability in GH responses. This maximum did not differ from that found in control subjects Baseline hormonal concentrations (18.0±3.1 mg/l, Table 2 ), although in this group peak GH was reached at 30-45 min. The AUC of GH The patients exhibited baseline plasma GH concentrasecretion in uraemic patients were also comparable tions similar to those found in healthy volunteers.
with the values found in healthy volunteers (14.4±2.9 IGF-I concentrations were higher in patients with vs 15.4±3.3 mg/h/l, Table 2 ). regard to values found in control subjects, although this difference did not reach statistical significance. The patients also showed plasma concentrations of free Responses to pirenzepine plus GHRH thyroxine and thyrotropin that were not different from Oral pirenzepine administration before GHRH injecthose found in normal subjects. However, prolactin tion produced an abolishment of GHRH-induced GH concentrations were significantly higher in uraemic release (maximum GH concentration <3 mg/l ) in all patients in relation to healthy volunteers ( Table 1) .
control subjects and in all but one of the uraemic patients. Therefore, GH peak reached after pirenzepine Responses to placebo plus GHRH plus GHRH was 3.8±2.2 mg/l (P<0.05 vs peak after placebo plus GHRH ) in patients and 1.8±0.3 mg/l In comparison with controls, GH responses to GHRH, (P<0.05 vs peak after placebo plus GHRH ) in conboth after placebo and after pirenzepine, were charactrols. This implies that the absolute decrement in GH terized by great interindividual variability in uraemic peak was −10.1±1.6 mg/l in patients and -16.2±2.9 mg/l in controls. The percent of suppression GHRH at 30-90 min in uraemic patients ( Figure 1A ) serum of substances with IGF-I-binding capacity or to the presence of high concentrations of IGF-I-binding and at 15-90 min in healthy subjects ( Figure 1B) .
In contrast, AUC of GH secretion was significantly proteins [8, 9] . Patients exhibited lower values of haemoglobin and haematocrit, thus indicating a moderate reduced both in uraemic patients (from 14.4± 2.9 mg/h/l to 4.1±2.0 mg/h/l, P<0.05) and in control anaemia, and higher prolactin levels as frequently occurs in uraemia [2, 8, 30] . Moreover, none of the subjects (from 15.4±3.3 mg/h/l to 2.0±0.3 mg/h/l, P<0.05). The absolute value and the percentage of patients were diabetic or were on erythropoietin suppression of AUC induced by pirenzepine was sim-therapy. We selected this group of clinically stable ilar in uraemic group and control group ( Table 2) . male patients in order to avoid variability in GH values Two uraemic patients complained of dryness in the derived from other conditions that affect GH secretion, mouth during the pirenzepine plus GHRH test. No such as obesity, malnutrition, diabetes, thyroid dyssubjetive side effects were reported in healthy function [12] or erythropoietin therapy [31] . Therefore, volunteers.
the limitations of this study are derived from the restricted number of patients and from the potentially limited sensitivity of the chosen study setting in Discussion detecting uraemic changes.
In these patients we found that GH responses to GHRH were quantitatively similar to those elicited in The clinical and analytical characteristics of the studied normal subjects, since there were no differences in subjects indicate that this group of uraemic male maximum GH concentration or in AUC of GH secrepatients on PD were well-nourished, non-obese, euthytion. This is in accordance with our previous studies roid, adequately dialysed and moderately anaemic. In in PD patients [31] and with those of other investigfact, we could not find any significant difference ators in haemodialysis patients [10, 11] . GH responses between patients and age-matched controls in serum were more sustained in patients on PD, as reported concentrations of albumin, total proteins, IGF-I, free previously [31] . thyroxine and thyrotropin. The slight and non-
The results given here clearly show that the pretreatsignificant elevation in IGF-I levels found in our patients may be due to the existence in the uraemic ment with pirenzepine, a muscarinic receptor-blocking Fig. 1. (A) Growth hormone responses to growth hormone-releasing hormone (GHRH; 100 mg, i.v., arrow) in a group of eight uraemic patients. Sixty minutes before (P, arrow) GHRH injection patients were given placebo (p.o., #) or pirenzepine (PZ; 100 mg, p.o., $). Each point represents the mean±SEM. *P<0.05. (B) As in panel (A), growth hormone responses to placebo plus GHRH (6) and to pirenzepine plus GHRH (+) in six healthy subjects. Each point represents the mean±SEM. *P<0.05. drug, produced the abolishment of GHRH-induced complete integrity of the cholinergic pathways would imply that the enhancement of central nervous system GH release in PD patients in a way similar to that found in healthy volunteers. Studies in animals have cholinergic activity by pyridostigmine, an indirect cholinergic agonist, gave rise to an increase in GH release demonstrated that the inhibitory effect of the antimuscarinic drug atropine on the GH response to GHRH in uraemic patients similar to that obtained in normal subjects. Information on this aspect is scanty. It has can be abolished by antisomatostatin antibodies [18] . Therefore, several groups of investigators have pro-been reported that pyridostigmine enhanced GHRHinduced GH release in a group uraemic children with posed that acetylcholine positively regulates GH secretion by decreasing hypothalamic somatostatinergic baseline blunted GH responses to GHRH, but failed to potentiate these responses in another group of tone [18, 26, 27] . In fact, it has been demonstrated that acetylcholine inhibits somatostatin release from rat children with normal GHRH responsiveness [44] . This suggests a decrease in somatostatinergic tone in these hypothalamic tissue in vitro [32] and modulates in vivo somatostatin effects on GHRH-stimulated GH release GHRH responder children. So far, however, no data are available in adult uraemic patients. in the rat [18, 19] .
The clear-cut pirenzepine-induced decrease in In conclusion, we have evaluated the effect of the cholinergic muscarinic antagonist pirenzepine on GH GHRH-induced GH release in PD patients suggests that GH secretion in uraemic patients is modulated, responses to its physiological releasing hormone in patients with chronic renal insufficiency undergoing at least in part, by cholinergic mechanisms, as it is in normal subjects. However, whether abnormal GH PD. Our data indicate that the stimulatory effect exerted by GHRH on GH secretion and its inhibition regulation in renal failure might be due to increased activity of cholinergic neurons or to diminished hypo-by pirenzepine are preserved in PD patients. These results suggest that the regulation of GH secretion in thalamic somatostatinergic function cannot be deduced from our findings. The pirenzepine-induced blunting uraemic subjects is highly responsive to selective muscarinic receptor blockade. in GH responses to its physiological releasing hormone and other stimuli, such as sleep, exercise, arginine,
